DBV Technologies Welcomes New Chief Human Resources Officer
DBV Technologies (NASDAQ: DBVT), a pioneering clinical-stage biopharmaceutical company, recently announced the strategic appointment of James Briggs as its Chief Human Resources Officer. This key move signifies the company’s commitment to bolstering its leadership team as it navigates essential transitions towards commercialization.
Briggs' Vision for DBV Technologies
James Briggs brings a wealth of experience in human resources to DBV Technologies, succeeding Caroline Daniere. His comprehensive background in human capital management positions him uniquely to oversee pivotal initiatives that will aid DBV in evolving from a development-focused organization into a commercially-oriented enterprise. In his role, Mr. Briggs will report directly to Daniel Tassé, the Chief Executive Officer, and will be an integral part of the Executive Committee.
CEO's Words on the Transition
Daniel Tassé, CEO of DBV Technologies, expressed his gratitude towards Caroline’s leadership, stating, "Her contributions were foundational to the culture we have today. James possesses a remarkable ability to identify talent and create effective solutions that drive performance and productivity. His proven expertise in aligning talent strategies with business goals will be crucial as we scale operations and prepare for future growth."
Background of James Briggs
In his most recent position as a Partner at East Bay Human Capital, James has honed his skills in organizational design and change management. His prior experience includes high-impact roles such as Chief Executive Officer at MNG Health, where he successfully directed the turnaround and sale of the company, and as Chief Human Resources Officer at Ciox Health and Ikaria Inc. Mr. Briggs has consistently demonstrated his ability to lead HR functions effectively, making him a valuable asset to DBV’s leadership.
Briggs on His Role
James expressed his enthusiasm about joining DBV Technologies during this pivotal phase, saying, "This is a crucial time as we transition from a focus on clinical development to establishing the necessary infrastructure for commercial success. I am thrilled to collaborate with this exceptional leadership team to further develop our organizational foundation in pursuit of bringing life-changing treatments to patients across the world."
DBV Technologies: A Leader in Biopharmaceutical Innovation
DBV Technologies is at the forefront of developing innovative treatment solutions for food allergies and immunologic conditions that present significant unmet medical needs. The company is particularly invested in its proprietary VIASKIN® patch technology, which presents a novel approach to treating food allergies through epicutaneous immunotherapy (EPIT). This method works by delivering small, controlled amounts of allergenic materials to the immune system via the skin, aiming to desensitize patients and mitigate the severe reactions associated with food allergies.
Commitment to Impactful Solutions
DBV's commitment to transforming the care of food allergy patients is evident, as the company is currently conducting clinical trials for its VIASKIN Peanut technology, targeting both toddlers and young children suffering from peanut allergies. By focusing on this vulnerable demographic, DBV is addressing a critical health issue that affects millions globally.
DBV Technologies’ Strategic Direction
Headquartered in Châtillon, France, DBV Technologies operates its North American branches from Warren, NJ. Alongside its innovative research and development efforts, the company continues to strengthen its market position, as evidenced by its shares being actively traded on multiple platforms, including Nasdaq and Euronext Paris. As it advances, DBV Technologies is poised for future growth, bolstered by the leadership of individuals like James Briggs.
Frequently Asked Questions
What is the recent appointment at DBV Technologies?
James Briggs has been appointed as the Chief Human Resources Officer at DBV Technologies, succeeding Caroline Daniere.
What role will James Briggs play at DBV Technologies?
Briggs will lead key HR initiatives, helping DBV transition from a development-stage to a commercial organization.
How does DBV Technologies approach the treatment of food allergies?
DBV uses its proprietary VIASKIN® patch technology to deliver therapies for food allergies, aiming to educate the immune system through non-invasive means.
What are the main focus areas for DBV Technologies?
DBV Technologies focuses on developing innovative treatment options specifically targeting food allergies and other immune-related conditions.
Where is DBV Technologies headquartered?
DBV Technologies is headquartered in Châtillon, France, with significant operations in North America.
